Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

被引：0
|
作者：
Goldberg, Stuart L. [1 ]
Mauro, Michael J. [2 ]
Cortes, Jorge E. [3 ]
Keating, Scott Justin [4 ]
Bhandari, Hitesh [5 ]
Chen, Clara [4 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] SmartAnalyst India Pvt Ltd, Gurgaon, India
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128290
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4151
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice
    Atallah, Ehab L.
    Wei, David
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Damon, Andrea
    Ferreira, Germano
    Guerin, Annie
    Jadhav, Kejal
    BLOOD, 2023, 142
  • [42] CYTOGENETIC AND MOLECULAR RESPONSES IN ITALIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN A PROSPECTIVE OBSERVATIONAL STUDY
    Abruzzese, E.
    Foreman, A.
    Gambacorti-Passerini, C.
    Gentilini, F.
    Liberati, A. M.
    Sica, S.
    Alimena, G.
    HAEMATOLOGICA, 2015, 100 : 129 - 129
  • [43] EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML)
    Chuah, C.
    Guerci-Bresler, A.
    Rosti, G.
    Simpson, D.
    Lustgarten, S.
    Trede, N.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Baccarani, M.
    Cortes, J. E.
    Guilhot, F.
    Hochhaus, A.
    Hughes, T.
    Kantarjian, H.
    Shah, N. P.
    Talpaz, M.
    Deininger, M. W.
    Lipton, J. H.
    HAEMATOLOGICA, 2014, 99 : 238 - 238
  • [44] SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD-OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB
    Stellato, D.
    McGarry, L.
    Huang, H.
    Hastings, S.
    Delea, T.
    HAEMATOLOGICA, 2017, 102 : 434 - 434
  • [45] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
  • [46] Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Deininger, Michael W.
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    Kantarjian, Hagop M.
    Guilhot, Francois
    BLOOD, 2013, 122 (21)
  • [47] Dose Modification Dynamics of Ponatinib in Patients with Chronic- Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials
    J.Jabbour, Elias
    W.Deininger, Michael
    bruzzese, Elisabetta A.
    Apperley, jane F.
    E.Cortes, Jorge
    Chuah, Charles
    J.DeAngelo, Daniel
    F.DiPersio, John
    Hochhaus, Andreas
    H.Lipton, Jeffrey
    E.Nicolini, Franck
    Ibarz, Javier Pinilla
    Rea, Delphine
    Rosti, Gianantonio
    Rousselot, Philippe
    J.Mauro, Michael
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Lu, Vickie
    Kantarjian, Hagop
    BLOOD, 2021, 138
  • [48] Discontinuation of Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice Following Updates to NCCN CML Practice Guidelines
    Atallah, Ehab
    Sadek, Islam
    Maegawa, Rodrigo
    Cao, Xiting
    Latremouille-Viau, Dominick
    Pivneva, Irina
    Rossi, Carmine
    Guerin, Annie
    Kota, Vamsi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S231 - S231
  • [49] Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.
    Roy, A.
    Shah, N. P.
    le Contra, P.
    Wang, X.
    Schiffer, C. A.
    Saglio, G.
    Lambert, A.
    Damokosh, A.
    Bahceci, E.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Delaying the initiation of dasatinib after imatinib failure has a negative impact on outcome for patients with chronic-phase chronic myeloid leukemia (CP-CML): results from a European observational study (FORTE; CA180-211)
    Niederwieser, D.
    Morra, E.
    Michallet, M.
    Marin, D.
    Hellmann, A.
    Schloegl, E.
    Bjoereman, M.
    Foryciarz, K.
    Ho, A.
    Kuliczkowski, K.
    Ossenkoppele, G.
    Gozzini, A.
    Gora-Tybor, J.
    Guerra, M. L.
    Verhoef, G.
    Roussou, P.
    Mori, A.
    van, Baardewjik M.
    Steegmann, J. L.
    ONKOLOGIE, 2011, 34 : 264 - 264
12345